by MM360 Staff | May 30, 2025 | Myeloma News
Source: Pharmacy Times articles The pharmacy is proud to be community focused and patient centered. Read More
by MM360 Staff | May 30, 2025 | Myeloma News
Source: Pharmacy Times articles Shore Medical Center enhances patient safety with a pharmacy-driven intravenous to oral opioid conversion protocol, minimizing risks and improving pain management. Read More
by MM360 Staff | May 30, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | May 30, 2025 | Myeloma News
Source: Pharmacy Times articles A panelist discusses how the PALOMA-3 study demonstrated that subcutaneous amivantamab is noninferior to intravenous (IV) administration with significantly lower infusion-related reaction (IRR) rates (13% vs 66%), shorter administration...
by MM360 Staff | May 30, 2025 | Myeloma News
Source: Pharmacy Times articles Panelists discuss how recent FDA approvals and evolving evidence for second-line treatments, including ruxolitinib, ibrutinib, and belumosudil, are reshaping chronic graft-vs-host disease (cGVHD) management by offering tailored,...
by MM360 Staff | May 30, 2025 | Myeloma News
Source: Pharmacy Times articles Panelists discuss how factors such as patient preferences, disease severity, organ-specific involvement, and adverse effect profiles influence the selection of second-line therapies for steroid-refractory chronic graft-vs-host disease...